Glofitamab for Chinese patients with relapsed or refractory DLBCL
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a drug called glofitamab for people with a type of lymphoma (DLBCL) that has come back or not responded to at least two prior treatments. The goal is to see if this drug can help shrink tumors or stop the disease from progressing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with a type of lymphoma called diffuse large B-cell lymphoma (DLBCL).
- Your lymphoma has come back or not improved after at least two rounds of treatment.
- You have at least one tumor that can be measured on scans.
- You are not pregnant or breastfeeding.
- You do not have an active or recent serious infection, or a condition that weakens your immune system.
- Your major organs (heart, lungs, kidneys, liver) are working well enough.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is looking at how well the drug glofitamab works in people whose diffuse large B-cell lymphoma (a common type of lymphoma) didn't respond to, or came back quickly after, their first therapy. The goal is to learn how effective and safe glofitamab is in the real world when it is added to standard care.
This study is testing a new combination of two treatments—glofitamab (a targeted antibody) and CAR-T cell therapy—for people with relapsed or refractory large B-cell lymphoma. It is for patients who have not responded to or have relapsed after at least one prior treatment and have certain high-risk features.
This study looks at how well a drug called Glofitamab works in Chinese adults with a type of lymphoma (diffuse large B-cell lymphoma) that has come back or not gotten better after one round of standard treatment. It will help doctors understand more about its effects in real-world settings.
This trial tests a combination of two drugs, glofitamab and chidamide, for people with diffuse large B-cell lymphoma (DLBCL) that has come back or not responded after at least two prior treatments. The goal is to see if this combination can help when other options have stopped working.
This study looks at how well the drug glofitamab works and how safe it is for people with a type of blood cancer called diffuse large B-cell lymphoma that has come back or hasn't gotten better after treatment. It's for adults in China who are either about to start glofitamab or have started it within the past 6 months.
This study looks at how well glofitamab works in real-world patients with a type of lymphoma that has come back or not responded to treatment. It includes adults who have already received obinutuzumab and at least one dose of glofitamab in a special access program.
Hear when a new DLBCL - Diffuse Large B Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.